PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50126F61020 — TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN is a federal award for Department of Health and Human Services (HHS) held by GLAXOSMITHKLINE LLC. Estimated value $493K ($493K obligated). Current period of performance ends Oct 29, 2026. Place of performance: DURHAM NC.

$493K
Estimated Value
Oct 29, 2026
PoP End / Expires

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

GLAXOSMITHKLINE LLC holds $2.8B across 206 federal awards, concentrated at Department of Health and Human Services (HHS). Recompete timing centers on the Oct 29, 2026 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract number75A50126F61020
AgencyDepartment of Health and Human Services (HHS)
IncumbentGLAXOSMITHKLINE LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV75A50122D00002
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startMar 13, 2026
PoP end (current)Oct 29, 2026
Obligated$493K
Current value$493K
Potential value$493K

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN

Recompete timing

Public
Expiring in 73 days

Current PoP ends Oct 29, 2026 (73 days remaining). Agencies typically plan 12–18 months ahead — at 2.4 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

GLAXOSMITHKLINE LLC$2.8B obligated across 206 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($2.8B) · all agencies
Department of Health and Human Services (HHS)$2.8B · 100%Department of Defense (DOD)$3.9M · 0%
Department of State (DOS)$1.8M · 0%
Department of Veterans Affairs (VA)$1.5M · 0%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75A50126F61020
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open GLAXOSMITHKLINE LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50126F61020?

75A50126F61020 (TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN) is a Department of Health and Human Services (HHS) award with an estimated value of $493K, currently held by GLAXOSMITHKLINE LLC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50126F61020?

GLAXOSMITHKLINE LLC is the incumbent with $2.8B across 206 related awards in SCOUT’s public footprint. The current period of performance ends Oct 29, 2026.

When does 75A50126F61020 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50122D00002-75A50126F61020